大剂量/常规剂量促红细胞生成素治疗癌性贫血的随机对比研究  

Randomized Comparison the Clinical Trial of High or Common-dose Erythromycin Treatment in Anemic Patients with Cancer

作　　者：王玉斌[1] 陈文俊[1] 郑维锷[1] 张武[1] 刘晓棠[1] 王建化[1] 李芙瑶[1] 孙洪雨[1] 王春妹[1] 

机构地区：[1]温州医学院附属三院,浙江瑞安325200

出　　处：《实用中西医结合临床》2007年第2期1-2,4,共3页Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine

基　　金：温州市科技局立项并资助课题(课题编号:Y2006A049)

摘　　要：目的:比较常规剂量重组人促红细胞生成素(rHuEPO)与大剂量rHuEPO治疗癌性贫血的疗效。方法:将血红蛋白(Hb)≤10.0g/dL的癌性贫血病人随机分为常规剂量rHuEPO组(A组:10000U/次,qod,8周)与大剂量rHuEPO组(B组:40000U/次,qod×3次,然后1次/周×7周),治疗不到8周者至Hb≥13.5g/dL时停药。每周复查血常规,rHuEPO治疗2周后补充铁剂(力蜚能胶囊150mg口服,1次/d)。结果:治疗开始的8周后评价疗效,A、B2组有效率分别为55.7%、73.3%,P<0.05;在治疗的第2、4、8周,B组平均Hb水平高于A组,差异均有显著性,在治疗的第6周2组差异无显著性。与治疗前基础水平相比,B组在治疗的第2周Hb即显著升高[(10.15±1.1)对(9.30±0.91),P<0.05)],而A组这种差异最早出现在第4周[(9.85±1.33)对(9.26±0.95),P<0.05)];另外,治疗的第2、4、6、8周,Hb的平均水平B组均高于A组(P<0.05)。2组未见有明显的副作用发生。结论:大剂量rHuEPO治疗癌性贫血的疗效要好于常规剂量,升高Hb的速度也比常规剂量要快,副作用少且可以耐受。Objective：To compare the hemoglobin （Hb） response to common-dose erythromycin （group A）and high-dose erythromycin （group B）,in anemic patients with cancer, Methods： Adults with solid tumors and baseline Hb 10g/dL were randomized to receive either EPO 40 000 U every 2 days three times （QOD× 3）,then once weekly （QW） or10 000U every 2 days （QOD） for up to 8 weeks. Observe the Hb level every week. Results ： The proportion of patients achieving a 2.0g/dL Hb rise by week 8 was significantly higher in group B （73.3%） than in group A （55.7%）, and group B patients achieved a 2.0g/dL Hb increase significantly earlier than group A （median, 33 days versus 45days）. The mean increase in Hb from baseline was significantly higher at weeks 2,4, 6 and the end of the study with high-dose erythromycin than with common-dose. There arc no obvious side effects in two groups. Conclusion ： The curative effect in guoup B is better than the guoup A and Hb in high-dose erythromycin group increase significantly earlier than those receiving common-dose,Side effects in Two groups could be toleration.

关 键 词：癌性贫血 重组人促红细胞生成素 药物疗法 随机对比研究 

分 类 号：R556.9[医药卫生—血液循环系统疾病]